Changing the nature of antibiotics, for the better.

MetalloBio is a medical company developing a breakthrough class of broad-spectrum antibacterial agents, representing the first major innovation in the field in nearly 50 years.

We are on a mission to fight the growing threat of ‘superbugs’. We are developing a brand-new class of infection-fighting treatments that work differently than any antibiotics used today.

Our powerful new drugs known as ‘KLS-1 Series’ compounds are specifically designed to treat the most stubborn, complicated infections that standard medicines can no longer keep up with.

We are also working on a second group of compounds, the KLS-2 Series group of compounds, which have been tuned for use in coatings for medical equipment. By applying these to apparatus such as catheters and joint implants, we can stop infections before they even start.

Our lead treatment KLS-116, named after our late founder Dr Kirsty Louise Smitten, doesn’t just attack a germ in one way, it has a ‘double-strike’ effect. This makes it incredibly hard for bacteria to develop resistance.

Many dangerous infections hide behind a slimy protective shield called a biofilm. While most drugs get bounced off this shield, our compounds are designed to punch right through it and destroy the bacteria hiding inside.